论文部分内容阅读
目的:探讨新型非甾体抗炎药塞来昔布在2型糖尿病中作用及其机制。方法:80例患者随机分为拜唐平+二甲双胍治疗方案组(A组)、塞来昔布联合拜唐平+二甲双胍治疗方案组(B组)及20例健康对照组。比较各组治疗前、后血糖、C-反应蛋白(C-Reaction protein,CRP)、核转录因子-κB mRNA水平,肿瘤坏死因子(TNF-α)、白介素-2(IL-2)、白介素-6(IL-6)含量水平的差异;比较各治疗组治疗前与治疗后上述各指标含量的差异。结果:治疗前各治疗组与健康对照组相比较血糖、CRP、血中NF-κBmRNA水平,TNF-α、IL-2、IL-6含量水平的差异均有显著性(P<0.05);各治疗组治疗前、后之间CRP、血中NF-κB mRNA水平,TNF-α、IL-2、IL-6含量水平的差异均有显著性(P<0.05);治疗后,治疗组1与治疗组2相比较,血糖差异无显著性(P<0.05)。结论:在2型糖尿病患者中存在明显的炎症反应过程,塞来昔布作为新型非甾体抗炎药,其不仅具有明显的抗炎症反应,且可降低患者的血糖水平。
Objective: To explore the role and mechanism of celecoxib, a new nonsteroidal anti-inflammatory drug, in type 2 diabetes mellitus. Methods: Eighty patients were randomly divided into three groups: metformin plus metformin (group A), celecoxib plus metformin plus metformin (group B), and 20 healthy controls. The levels of blood glucose, C-Reaction protein (CRP), nuclear transcription factor-κB mRNA, tumor necrosis factor (TNF-α), interleukin-2 (IL- 6 (IL-6) content levels of different treatment groups compared before and after treatment of the above indicators of the difference. Results: The levels of blood glucose, CRP, blood levels of NF-κB and the levels of TNF-α, IL-2 and IL-6 in the treatment groups before treatment were significantly higher than those in the healthy controls (P <0.05) The levels of CRP, NF-κB mRNA, TNF-α, IL-2 and IL-6 in the treatment group before and after treatment were significantly different (P <0.05). After treatment, There was no significant difference in blood glucose between two groups (P <0.05). CONCLUSIONS: There is a clear inflammatory response in patients with type 2 diabetes. Celecoxib, as a new non-steroidal anti-inflammatory drug, not only has a significant anti-inflammatory response, but also reduces blood glucose levels in patients.